Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LILAC - TB : Lowering InterLeukin-1 Receptor Antagonist Concentrations After TB Treatment Onset : a Proof of Concept Study in Cambodia and Ivory Coast (ANRS 12394)

NCT04015713 is registered in ClinicalTrials.gov with ANRS, Emerging Infectious Diseases as lead sponsor.

NCT NCT04015713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04015713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LILAC - TB : Lowering InterLeukin-1 Receptor Antagonist Concentrations After TB Treatment Onset : a Proof of Concept Study in Cambodia and Ivory Coast (ANRS 12394)
Lead sponsor
ANRS, Emerging Infectious Diseases
Phase
Observational
Overall status
Unknown status
Start date
January 21, 2020
Completion date
March 31, 2021
Enrollment
100 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis